

Announcement of Unaudited Condensed Financial Statements for The Six Months And Full Year Ended 31 December 2024

Table of contents

| | | |
|----|---|----|
| A. | Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income | 2 |
| B. | Condensed Statements of Financial Position | 3 |
| C. | Condensed Statements of Changes in Equity | 4 |
| D. | Condensed Consolidated Statement of Cash Flows | 6 |
| E. | Notes to Condensed Consolidated Financial Statements | 8 |
| F. | Other information required by Listing Rule Appendix 7C | 17 |

A. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

| | Note | Unaudited | Unaudited | Group | | Audited | + / (-) % |
|---|------|-------------------------------------|-------------------------------------|---|--------------------------------------|-----------|--------------|
| | | 6 months ended 31 Dec 2024 | 6 months ended 31 Dec 2023 | Unaudited 12 months ended 31 Dec 2024 | 12 months ended 31 Dec 2023 | | |
| | | RMB'000 | RMB'000 | | | RMB'000 | |
| Revenue | 4 | 181,590 | 205,436 | (12) | 243,757 | 598,563 | (59) |
| Cost of sales | | (212,138) | (318,415) | (33) | (326,014) | (858,741) | (62) |
| Gross loss | | (30,548) | (112,979) | (73) | (82,257) | (260,178) | (68) |
| Other income | | 4,392 | 9,652 | (54) | 10,448 | 24,244 | (57) |
| Distribution costs | | (1,021) | (4,103) | (75) | (2,677) | (11,526) | (77) |
| Administrative expenses | | (12,6521) | (19,544) | (35) | (27,573) | (37,559) | (27) |
| Other expenses | | (12,279) | (6,951) | 77 | (13,133) | (6,951) | 89 |
| Reversal of impairment loss/(impairment loss) on financial assets | | 6,190 | (25,839) | N.M | 6,190 | (25,840) | N.M |
| Finance costs | | (1,115) | (918) | 21 | (2,085) | (2,615) | (20) |
| Share of results of associated companies | | (13,636) | (32,481) | (58) | (34,117) | (26,499) | 29 |
| Loss before tax | 6 | (60,668) | (193,163) | (69) | (145,204) | (346,924) | (58) |
| Tax (expense)/credit | 7 | (2,596) | 8,808 | N.M. | (2,596) | 195 | N.M. |
| Loss and total comprehensive loss for the period/year | | (63,264) | (184,355) | (66) | (147,800) | (346,729) | (57) |
| Loss and total comprehensive loss for the period/year attributable to: | | | | | | | |
| Equity holders of the Company | | (63,264) | (182,333) | | (147,800) | (344,643) | |
| Non-controlling interest | | - | (2,022) | | - | (2,086) | |
| | | (63,264) | (184,355) | | (147,800) | (346,729) | |
| Loss per share for loss for the financial period/year attributable to equity holders of the Company (in RMB cents per share) | | | | | | | |
| Basic and diluted | 8 | (3.18) | (9.17) | | (7.43) | (17.33) | |

N.M.: not meaningful

B. Condensed Statements of Financial Position

| | Note | Group | | Company | |
|---|------|--------------------------|------------------------|--------------------------|------------------------|
| | | Unaudited 31 Dec 2024 | Audited 31 Dec 2023 | Unaudited 31 Dec 2024 | Audited 31 Dec 2023 |
| | | RMB'000 | RMB'000 | RMB'000 | RMB'000 |
| ASSETS | | | | | |
| Current assets | | | | | |
| Cash and cash equivalents | 11 | 515,933 | 684,026 | 62,437 | 70,495 |
| Trade and other receivables | | 87,008 | 207,382 | 476 | 301 |
| Inventories | | 23,011 | 31,775 | - | - |
| Total current assets | | 625,952 | 923,183 | 62,913 | 70,796 |
| Non-current assets | | | | | |
| Property, plant and equipment | 12 | 396,704 | 315,576 | - | - |
| Right-of-use assets | | 6,259 | - | 551 | - |
| Land use rights | | 1,360 | 1,405 | - | - |
| Investment in subsidiary company | | - | - | 257,570 | 257,570 |
| Investment in associated companies | | 14,781 | 48,898 | 14,781 | 48,898 |
| Total non-current assets | | 419,104 | 365,879 | 272,902 | 306,468 |
| Total assets | | 1,045,056 | 1,289,062 | 335,815 | 377,264 |
| LIABILITIES AND EQUITY | | | | | |
| Current liabilities | | | | | |
| Bank borrowings | 13 | 184,679 | 199,874 | - | - |
| Trade and other payables | | 132,036 | 245,242 | 1,021 | 1,481 |
| Contract liabilities | | 5,603 | 12,099 | - | - |
| Lease liabilities | | 3,447 | - | 458 | - |
| Total current liabilities | | 325,765 | 457,215 | 1,479 | 1,481 |
| Non-current liabilities | | | | | |
| Bank borrowings | 13 | 99,350 | 66,010 | - | - |
| Lease liabilities | | 1,841 | - | 118 | - |
| Deferred tax liabilities | | 63 | - | - | - |
| Total non-current liabilities | | 101,254 | 66,010 | 118 | - |
| Total liabilities | | 427,019 | 523,225 | 1,597 | 1,481 |
| Capital and reserves | | | | | |
| Share capital | 14 | 709,977 | 709,977 | 709,977 | 709,977 |
| Accumulated losses | | (202,646) | (54,846) | (375,759) | (334,194) |
| Statutory reserve fund | | 110,706 | 110,706 | - | - |
| Equity attributable to equity holders of the Company | | 618,037 | 765,837 | 334,218 | 375,783 |
| Total liabilities and equity | | 1,045,056 | 1,289,062 | 335,815 | 377,264 |

C. Condensed Statements of Changes in Equity

| | <u>Note</u> | Share capital | (Accumulated losses)/ Retained earnings | Statutory reserve fund | Equity attributable to equity holders of the Company | Non-controlling interests | Total equity |
|--|-------------|----------------|--|------------------------|--|---------------------------|----------------|
| | | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 |
| Group | | | | | | | |
| Balance at 1 January 2024 (Audited) | | 709,977 | (54,846) | 110,706 | 765,837 | - | 765,837 |
| Loss and total comprehensive loss for the financial year | | - | (147,800) | - | (147,800) | - | (147,800) |
| Balance at 31 December 2024 (Unaudited) | | 709,977 | (202,646) | 110,706 | 618,037 | - | 618,037 |
| Balance at 1 January 2023 (Audited) | | 709,977 | 401,655 | 110,706 | 1,222,338 | (1,389) | 1,220,949 |
| Loss and total comprehensive loss for the financial year | | - | (344,643) | - | (344,643) | (2,086) | (346,729) |
| Liquidation of subsidiary companies | | - | - | - | - | 3,475 | 3,475 |
| Dividends | 9 | - | (111,858) | - | (111,858) | - | (111,858) |
| Balance at 31 December 2023 (Audited) | | 709,977 | (54,846) | 110,706 | 765,837 | - | 765,837 |

C. Condensed Statements of Changes in Equity

| | Note | Share capital RMB'000 | Accumulated losses RMB'000 | Total equity RMB'000 |
|---|------|-----------------------------|----------------------------------|-------------------------|
| Company | | | | |
| Balance at 1 January 2024 (Audited) | | 709,977 | (334,194) | 375,783 |
| Loss and total comprehensive loss for the financial year | | - | (41,565) | (41,565) |
| Balance at 31 December 2024 (Unaudited) | | 709,977 | (375,759) | 334,218 |
| Balance at 1 January 2023 (Audited) | | 709,977 | (322,812) | 387,165 |
| Profit and total comprehensive income for the financial year | | - | 100,476 | 100,476 |
| Dividends | 9 | - | (111,858) | (111,858) |
| Balance at 31 December 2023 (Audited) | | 709,977 | (334,194) | 375,783 |

D. Condensed Consolidated Statement of Cash Flows

| | Group | |
|---|--|--|
| | Unaudited 12 months ended 31 Dec 2024 | Audited 12 months ended 31 Dec 2023 |
| Note | RMB'000 | RMB'000 |
| Cash flows from operating activities | | |
| Loss before tax | (145,204) | (346,924) |
| Adjustments for: | | |
| Amortisation of land use rights | 45 | 644 |
| Financing bank charges | 305 | 632 |
| Depreciation of property, plant and equipment | 20,351 | 22,536 |
| Depreciation of right-of-use assets | 4,501 | - |
| Loss on disposal of property, plant and equipment | 2,629 | 3,380 |
| Impairment loss on property plant and equipment (Reversal of impairment loss)/impairment loss on financial assets (net) | 8,759 (6,190) | - 25,840 |
| Interest expenses on bank borrowings | 1,400 | 1,983 |
| Interest expenses on lease liabilities | 380 | - |
| Interest income | (8,227) | (15,362) |
| Inventories written down | 563 | 9,686 |
| Share of results of associated companies | 34,117 | 26,499 |
| Gain on liquidation of subsidiaries | - | (796) |
| Unrealised loss/(gain) on foreign exchange | 323 | (2,473) |
| Operating cash flows before movement in working capital | (86,248) | (274,355) |
| Inventories | 8,201 | 1,326 |
| Receivables | 126,724 | 254,601 |
| Payables and contract liabilities | (135,953) | (289,642) |
| Cash used in operations | (87,276) | (308,070) |
| Interest received | 8,227 | 15,362 |
| Income tax paid | (2,533) | (92,943) |
| Net cash used in operating activities | (81,582) | (385,651) |
| Cash flows from investing activities | | |
| Advances to associated company, net | (163) | (200) |
| Net cash outflow on liquidation of subsidiaries | - | (318) |
| Proceeds from disposal of property, plant and equipment | 670 | 394 |
| Purchases of property, plant and equipment | (90,051) | (125,578) |
| Net cash used in investing activities | (89,544) | (125,702) |

A

D. Condensed Consolidated Statement of Cash Flows (cont'd)

| | Note | Group | |
|---|------|------------------|------------------|
| | | Unaudited | Audited |
| | | 12 months ended | 12 months ended |
| | | 31 Dec 2024 | 31 Dec 2023 |
| | | RMB'000 | RMB'000 |
| Cash flows from financing activities | | | |
| Advance payment for right-of-use assets | | (746) | - |
| Dividends paid | 9 | - | (111,858) |
| Drawdown of bank borrowings | | 178,390 | 66,010 |
| Repayment of bank borrowings | | (99,970) | (10,000) |
| Decrease/(increase) in pledged fixed deposits | | 29,526 | (21,258) |
| Drawdown of bills payables to banks | | 165,944 | 301,397 |
| Repayment of bill payables to banks | | (226,219) | (226,165) |
| Repayment of lease liabilities | | (4,746) | - |
| Refund of deposit paid to secure bank borrowings | | - | 5,000 |
| Interest expenses on bank borrowings paid | | (8,628) | (3,226) |
| Interest expenses on lease liabilities paid | | (380) | - |
| Financing bank charges paid | | (305) | (632) |
| Net cash generated from/(used in) financing activities | | 32,866 | (732) |
| Net decrease in cash and cash equivalents | | (138,260) | (512,085) |
| Cash and cash equivalents at beginning of financial year | | 598,066 | 1,107,623 |
| Effect of exchange rate changes on cash and cash equivalents | | (307) | 2,528 |
| Cash and cash equivalents at end of financial year | 11 | 459,499 | 598,066 |
| Note A: | | | |
| <u>Purchases of property, plant and equipment ("PPE")</u> | | | |
| Aggregate cost of PPE acquired | | 113,537 | 187,303 |
| Add: Outstanding payables at 1 January | | 62,608 | 29,415 |
| Less: Outstanding payables related to former subsidiary companies that liquidated during the financial year | | - | (27,289) |
| Less: Outstanding payables at 31 December | | (78,866) | (62,608) |
| Less: Capitalised borrowing costs | | (7,228) | (1,243) |
| Net cash outflow for purchases of PPE | | 90,051 | 125,578 |

E. Notes to the Condensed Consolidated Financial Statements

1 Corporate information

Jiutian Chemical Group Limited (the “**Company**”) is incorporated and domiciled in Singapore and is listed on the Singapore Exchange Securities Trading Limited (“**SGX-ST**”). These condensed consolidated financial statements as at and for the six months and full year ended 31 December 2024 comprise the Company and its subsidiaries (Collectively, the “**Group**”).

The principal activity of the Company is that of investment holding. The principal activity of the subsidiary company is production, sale and service of industrial methanol, methylamine, Dimethylformamide (“**DMF**”) and gas and trading for chemical products.

2. Basis of preparation

The condensed financial statements for the six months and full year ended 31 December 2024 have been prepared in accordance with Singapore Financial Reporting Standards (International) (“**SFRS(I)**”) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2023.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The financial statements of the Group and the Company are presented in Chinese Renminbi (“**RMB**”), which is the functional currency of the Company, its subsidiary company and associated companies. All financial information presented in RMB have been rounded to the nearest thousand (RMB’000), unless otherwise stated.

2.1. *New and amended standards adopted by the Group*

There has been no change in the accounting policies and methods of computation adopted by the Group for the current reporting period compared with the audited financial statements for the year ended 31 December 2023, except for the adoption of new or revised SFRS(I) and Interpretations of SFRS(I) (“**INT SFRS(I)**”) that are mandatory for the financial year beginning on or after 1 January 2024. The adoption of these SFRS(I) and INT SFRS(I) has no significant impact on the Group.

E. Notes to the Condensed Consolidated Financial Statements

2. Basis of preparation (cont'd)

2.2. Use of judgements and estimates

In preparing the condensed financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2023.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment and revenue information

The Group is principally engaged in manufacturing and selling of chemical-based products, i.e., methylamine and DMF and trading of chemical products. The reportable segments are manufacturing and selling of chemical-based products and trading of chemical products.

| | 2H2024 | | Consolidated RMB'000 |
|--|--|---|-------------------------|
| | Manufacturing and selling of chemical-based products RMB'000 | Trading of chemical products RMB'000 | |
| Revenue | | | |
| Sales to external customers | 2,636 | 178,954 | 181,590 |
| Segment (loss)/profit, net of tax | (64,339) | 1,075 | (63,264) |
| Depreciation of property, plant and equipment | 12,013 | - | 12,013 |
| Finance costs | 1,115 | - | 1,115 |
| Interest income | (4,526) | - | (4,526) |
| Depreciation of right-of-use assets | 4,501 | - | 4,501 |
| Impairment loss on property, plant and equipment | 8,759 | - | 8,759 |
| Loss on disposal of property, plant and equipment | 1,979 | - | 1,979 |
| Reversal of impairment loss on financial assets (net) | (6,190) | - | (6,190) |
| Share of results of associated companies | 13,636 | - | 13,636 |
| Other significant non-cash expenses | 286 | - | 286 |

E. Notes to the Condensed Consolidated Financial Statements

4. Segment and revenue information(cont'd)

| | FY2024 | | |
|---|---|---|-------------------------|
| | Manufacturing and selling of chemical-based products RMB'000 | Trading of chemical products RMB'000 | Consolidated RMB'000 |
| Revenue | | | |
| Sales to external customers | 49,168 | 194,589 | 243,757 |
| Segment (loss)/profit, net of tax | (149,200) | 1,400 | (147,800) |
| Depreciation of property, plant and equipment | 20,351 | - | 20,351 |
| Finance costs | 2,085 | - | 2,085 |
| Interest income | (8,227) | - | (8,227) |
| Depreciation of right-of-use assets | 4,501 | - | 4,501 |
| Impairment loss on property, plant and equipment | 8,759 | - | 8,759 |
| Loss on disposal of property, plant and equipment | 2,629 | - | 2,629 |
| Reversal of impairment loss on financial assets (net) | (6,190) | - | (6,190) |
| Share of results of associated companies | 34,117 | - | 34,117 |
| Other significant non-cash expenses | 608 | - | 608 |
| Segment assets | 1,038,008 | 7,048 | 1,045,056 |
| Segment assets include: | | | |
| Investment in associated companies | 14,781 | - | 14,781 |
| Additions to non-current assets | 124,297 | - | 124,297 |
| Segment liabilities | 426,956 | - | 426,956 |
| Unallocated liabilities | | | 63 |
| Total liabilities | | | 427,019 |

Geographical information

The Group's revenue, expenses, results, assets and liabilities and capital expenditures are predominantly attributable to a single geographical region, the People's Republic of China ("PRC"), which is the Group's principal place of business and operations. Therefore, no analysis by geographical region is presented.

Revenue information

Revenue represents the amount received or receivable from sales of goods, net of sales related taxes.

E. Notes to the Condensed Consolidated Financial Statements

4. Segment and revenue information (cont'd)

Disaggregation of Revenue

The following table provides a disaggregation disclosure of the Group's revenue by major product of the Group.

| | Group | | | |
|---|--------------------------------|--------------------------------|--------------------------------|------------------------------|
| | Unaudited 2H2024 RMB'000 | Unaudited 2H2023 RMB'000 | Unaudited FY2024 RMB'000 | Audited FY2023 RMB'000 |
| Manufacturing and selling of chemical-based products | | | | |
| Methylamine | 124 | 128,884 | 39,223 | 380,440 |
| DMF | - | 69,585 | 7,045 | 206,568 |
| Others | 2,512 | 6,967 | 2,900 | 11,555 |
| | 2,636 | 205,436 | 49,168 | 598,563 |
| Trading of chemical products | | | | |
| Methylamine | 4,863 | - | 9,005 | - |
| DMF | 8,234 | - | 19,727 | - |
| Others | 165,857 | - | 165,857 | - |
| | 178,954 | - | 194,589 | - |
| | 181,590 | 205,436 | 243,757 | 598,563 |

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 December 2024 and 31 December 2023:

| | Group | | Company | |
|------------------------------|-------------------------------------|-----------------------------------|-------------------------------------|-----------------------------------|
| | Unaudited 31 Dec 2024 RMB'000 | Audited 31 Dec 2023 RMB'000 | Unaudited 31 Dec 2024 RMB'000 | Audited 31 Dec 2023 RMB'000 |
| <i>Financial assets</i> | | | | |
| At amortised cost | 541,336 | 819,978 | 62,846 | 70,735 |
| <i>Financial liabilities</i> | | | | |
| Amortised cost | 420,756 | 509,740 | 1,597 | 1,481 |

E. Notes to the Condensed Consolidated Financial Statements

6. Loss before taxation

6.1 Significant items

| | Group | | | |
|---|--------------------------------|--------------------------------|--------------------------------|------------------------------|
| | Unaudited 2H2024 RMB'000 | Unaudited 2H2023 RMB'000 | Unaudited FY2024 RMB'000 | Audited FY2023 RMB'000 |
| Loss before tax is arrived at after charging/(crediting): | | | | |
| Amortisation of land use rights | (277) | 322 | 45 | 644 |
| Depreciation of property, plant and equipment | 12,013 | 12,771 | 20,351 | 22,536 |
| Depreciation of right-of-use assets | 4,501 | - | 4,501 | - |
| Loss on disposal of property, plant and equipment | 1,979 | 3,380 | 2,629 | 3,380 |
| Impairment loss on property, plant and equipment | 8,759 | - | 8,759 | - |
| Reversal of impairment loss on financial assets | (6,365) | - | (6,365) | - |
| Impairment loss on financial assets | 175 | 25,839 | 175 | 25,840 |
| Interest expenses on bank borrowings | 524 | 528 | 1,400 | 1,983 |
| Interest expenses on lease liabilities | 380 | - | 380 | - |
| Interest income | (4,526) | (6,619) | (8,227) | (15,362) |
| Inventories written down | 563 | 9,686 | 563 | 9,686 |
| Gain on liquidation of subsidiaries | - | (796) | - | (796) |
| Net loss/(gain) on foreign exchange | 103 | (509) | 307 | (5,550) |

E. Notes to the Condensed Consolidated Financial Statements
6. Loss before taxation (cont'd)
6.2 Related party transactions

| Group | Unaudited FY2024 RMB'000 | Audited FY2023 RMB'000 |
|--|---|---------------------------------------|
| <i>With associated companies (subsidiary companies of Henan Energy and Chemical Industry Group Co., Ltd. ("HNEC"))</i> | | |
| Sales of goods | 10,854 | 62,479 |
| Purchases of goods | 19,383 | 274,775 |
| Rental expense | 957 | 1,220 |
| Exchange of bills for cash | 44,608 | - |
| Impairment loss on financial assets | 163 | 25,840 |
| Advances given to, net | 163 | 200 |
| | | |
| <i>With other subsidiary companies of HNEC</i> | | |
| Sales of goods | 3,524 | 10,352 |
| Purchases of goods | 24,877 | 44,586 |
| Rental income | 269 | 882 |
| Rental expense | 6,514 | 4,798 |
| Exchange of bills for cash | 15,300 | - |
| Exchange of cash for bills | - | 6,700 |
| | | |
| <i>With former subsidiary companies of the Group</i> | | |
| Advances given to, net | 139 | - |
| Recovery of receivables previously impaired | 6,365 | - |

7. Tax expense/(credit)

The Group calculates the income tax expense/(credit) using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense/(credit) in the condensed consolidated statement of profit or loss are:

| | Group | | | |
|-------------------------------------|---|---|---|---------------------------------------|
| | Unaudited 2H2024 RMB'000 | Unaudited 2H2023 RMB'000 | Unaudited FY2024 RMB'000 | Audited FY2023 RMB'000 |
| Current income tax expense/(credit) | 2,533 | (3,158) | 2,533 | (1,295) |
| Withholding tax expense | - | - | - | 6,750 |
| Deferred income tax | 63 | (5,650) | 63 | (5,650) |
| | 2,596 | (8,808) | 2,596 | (195) |

E. Notes to the Condensed Consolidated Financial Statements

8. Loss per share (LPS)

The calculation of the basic and diluted loss per share attributable to the ordinary equity holders of the Company is based on the following:

| | Group | | | |
|--|---------------------|---------------------|---------------------|-------------------|
| | Unaudited 2H2024 | Unaudited 2H2023 | Unaudited FY2024 | Audited FY2023 |
| Loss for the financial period/year attributable to equity holders of the Company (RMB'000) | (63,264) | (182,333) | (147,800) | (344,643) |
| Weighted average number of ordinary shares ('000) | 1,988,444 | 1,988,444 | 1,988,444 | 1,988,444 |
| Loss per share (RMB cents) | (3.18) | (9.17) | (7.43) | (17.33) |

The basic and diluted LPS are the same as there were no potentially dilutive ordinary shares outstanding during the respective financial years.

9. Dividends

| | Group and Company | |
|--|--------------------------------|------------------------------|
| | Unaudited FY2024 RMB'000 | Audited FY2023 RMB'000 |
| Ordinary dividends paid: | | |
| Interim tax-exempt dividends paid in respect of the current financial year of SGD Nil (2023: SGD 0.0090) per share | - | 95,877 |
| Final tax-exempt dividends paid in respect of the previous financial year of SGD Nil (2022: SGD 0.0015) per share | - | 15,981 |
| | - | 111,858 |

10. Net Asset Value

| | Group | | Company | |
|--|-----------------------------|---------------------------|-----------------------------|---------------------------|
| | Unaudited 31 Dec 2024 | Audited 31 Dec 2023 | Unaudited 31 Dec 2024 | Audited 31 Dec 2023 |
| Net asset value per ordinary share (RMB cents) | 31.08 | 38.51 | 16.81 | 18.90 |

Net asset value per ordinary share as at 31 December 2024 and 31 December 2023 have been computed based on total issued shares of 1,988,444,000.

E. Notes to the Condensed Consolidated Financial Statements

11. Cash and cash equivalents

| | Group | | Company | |
|---|--|--------------------------------------|--|--------------------------------------|
| | Unaudited 31 Dec 2024 RMB'000 | Audited 31 Dec 2023 RMB'000 | Unaudited 31 Dec 2024 RMB'000 | Audited 31 Dec 2023 RMB'000 |
| Cash on hand and at bank | 400,414 | 529,620 | 3,352 | 2,049 |
| Fixed deposits | 115,519 | 154,406 | 59,085 | 68,446 |
| | 515,933 | 684,026 | 62,437 | 70,495 |
| Pledged fixed deposits | (56,434) | (85,960) | - | - |
| Cash and cash equivalents in the consolidated statement of cash flows | 459,499 | 598,066 | 62,437 | 70,495 |

12. Property, plant and equipment

During the full year ended 31 December 2024, the Group acquired property, plant and equipment amounting to RMB 113.54 million (31 December 2023: RMB 187.30 million) in relation to the construction of new 100,000 tons methylamine production plant, and provided an impairment loss of RMB 8.76 million (31 December 2023: Nil).

13. Bank borrowings

| | Group | |
|--|-------------------------------------|-----------------------------------|
| | Unaudited 31 Dec 2024 RMB'000 | Audited 31 Dec 2023 RMB'000 |
| <u>Amount repayable within one year or on demand</u> | | |
| Bank borrowings | 95,020 | 49,940 |
| Bills payable to banks | 89,659 | 149,934 |
| | 184,679 | 199,874 |
| <u>Amount repayable after one year</u> | | |
| Bank borrowings | 99,350 | 66,010 |

Security for bank borrowings

As at 31 December 2023, there were RMB 49.94 million short-term borrowings guaranteed by the Group's related parties, Anyang Chemical Industry Group Co., Ltd. ("Anhua") and its associated company, Anyang Jiulong Chemical Co., Ltd ("Anyang Jiulong"). The borrowings were fully repaid during FY2024.

As at 31 December 2024, there were RMB 45 million short-term borrowings (31 December 2023: Nil) guaranteed by the Group's related parties, Henan Energy and Chemical Industry Group Co., Ltd. The borrowings are payable in FY2025.

As at 31 December 2024, there were RMB 149.37 million (31 December 2023: RMB 66.01 million) bank borrowings were unsecured, and scheduled to be repaid from FY2024 to FY2028.

Security for bills payable to banks

Bills payable to banks have an average maturity period of 90 to 180 days and are interest-free as repayments will be made within the credit period. The bills payable to banks are secured by pledged bank deposits amounting of RMB 56.43 million (31 December 2023: RMB 85.96 million).

E. Notes to the Condensed Consolidated Financial Statements

14. Share capital

| | Group and Company | |
|--|-----------------------------|---------|
| | 31 Dec 2024 and 31 Dec 2023 | |
| | Number of shares '000 | RMB'000 |
| Issued and paid-up capital: | | |
| At beginning and end of the financial period | 1,988,444 | 709,977 |

All issued shares are fully paid ordinary shares with no par value.

The holders of ordinary shares are entitled to receive dividends as and when declared by the Company. All ordinary shares carry one vote per share without restrictions.

15. Subsequent events

There are no known subsequent events which have led to adjustments to this set of financial statements.

F. Other Information Required by Listing Rule Appendix 7C

1(a)(i) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

| | Number of shares | Issued and paid-up share capital |
|---|---------------------|-------------------------------------|
| | RMB | |
| As at 31 December 2024 and 30 June 2024 | 1,988,444,000 | 709,976,678 |

There were no outstanding options, convertibles, treasury shares and subsidiary holdings as at 31 December 2024 and 31 December 2023.

1(a)(ii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

There were no treasury shares as at 31 December 2024 and 31 December 2023. The total number of issued shares of the Company are:

| | Number of shares | Issued and paid-up share capital |
|---|---------------------|-------------------------------------|
| | RMB | |
| As at 31 December 2024 and 31 December 2023 | 1,988,444,000 | 709,976,678 |

1(a)(iii) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable. The Company did not have any treasury shares during and as at the end of the financial year reported on.

1(a)(iv) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable. The Company did not have any subsidiary holdings during and as at the end of the financial year reported on.

F. Other Information Required by Listing Rule Appendix 7C

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The condensed consolidated statement of financial position of Jiutian Chemical Group Limited and its subsidiaries as at 31 December 2024 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the financial year ended 31 December 2024 and explanatory notes have not been audited or reviewed.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable as the 2H2024 and FY2024 figures have not been audited or reviewed.

3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:—

- (a) Updates on the efforts taken to resolve each outstanding audit issue.**
- (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.**

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable. The latest audited financial statements as at 31 December 2023 have an unmodified opinion.

4.A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the Group during the financial period reported on.**

Review of performance of the Group

Commentaries on performance

FY2024 vs FY2023

The sharp decline in revenue from our main products, Dimethylformamide (“DMF”) and Methylamine, was driven by management’s decision to halt production of these products since 2Q2024 to minimize losses amid depressed pricing. These low prices were primarily driven by an industry-wide softening in demand due to China’s overall weak economy and further exacerbated by increased supply from new competitors. Additionally, the production pause enabled the Group to take advantage of the market downturn by refining production processes and enhancing efficiency. Revenue shortfalls were partially offset by trading income from chemical products, a strategy the Group adopted to diversify its earnings base.

The significant drop in the cost of sales primarily mirrors the decline in revenue.

Resulting from a combination of the above factors, the Group’s suffered a gross loss.

F. Other Information Required by Listing Rule Appendix 7C

Commentaries on performance (cont'd)

FY2024 vs FY2023

Other income decreased primarily due to lower interest income from reduced bank balances in FY2024 and the absence of foreign exchange gains.

Distribution costs decrease was mainly due to lower transportation cost incurred arose from lower sales volume during FY2024.

Administrative expenses decrease was mainly due to the effect of management's reduction in operating costs during FY2024.

Share of result of associated companies was arising from the Company's 49% associated company, Anyang Jiulong Chemical Co., Ltd. Share of losses in FY2024 mainly due to low revenue and capacity utilisation arising from challenging business environment.

The increase in other expenses in FY2024 was mainly due to the impairment loss of property, plant and equipment partially offset by decrease in loss on disposal of property, plant and equipment and inventories written down.

The reversal of impairment loss on financial assets in FY2024 was primarily due to the recovery of receivables of RMB 6.37 million from a former subsidiary company.

The decrease in finance costs compared to FY2023 was mainly due to lower bank borrowings for working capital purposes during FY2024.

As a result of the above, the Group recorded a net loss of RMB 147.8 million attributable to Shareholders for FY2024.

Commentaries on balance sheet

The Group's year on year increase in non-current assets as at 31 December 2024 was mainly due to:

- a) acquisition of property, plant and equipment related to the construction of the new 100,000 tons Methylamine plant
- b) right-of-use assets were recorded in accordance with SFRS(I) 16.
- c) partially offset with a decrease in investment in an associated company due to the share of loss from an associated company in FY2024

The Group's year on year decrease in current assets as at 31 December 2024 was largely attributed to:

- a) a decrease in cash and cash equivalents due largely to cash used in operating activities and investing activities as presented in the consolidated statement of cash flows.
- b) a decrease in trade and other receivables, was driven by the halt in main product production, reduced business activity, and the collection of outstanding receivables.
- c) a decrease in inventories mainly due to lesser inventories kept as at 31 December 2024.

F. Other Information Required by Listing Rule Appendix 7C

Commentaries on balance sheet

The Group's year on year decrease in current liabilities as at 31 December 2024 was largely attributed to:

- a) a decrease in gross trade and other payables and contract liabilities due to Anyang Jiutian temporary ceased its production as mentioned above.
- b) a decrease in bank borrowings mainly due to lesser bill payables to banks were issued as Anyang Jiutian temporary ceased its production partially offset with the reclassification of bank loans from non-current to current liabilities amounting to RMB 50.02 million related to the construction of new 100,000 tons methylamine plant.
- c) partially offset against the lease liabilities recorded in accordance with SFRS(I) 16.

The Group's increase in non-current liabilities was primarily due to a drawdown of bank loans amounting to RMB133.39 million for the construction of a new 100,000-ton methylamine plant, along with lease liabilities recorded in accordance with SFRS(I) 16. This increase was partially offset by the reclassification of bank borrowings from non-current to current liabilities and repayment of bank borrowings.

The Group is in a net current assets position as at 31 December 2024 of RMB 300.19 million.

Commentaries on cash flow

Net cash used in operating activities in FY2024 was mainly due to net losses generated in the financial year,

Net cash used in investing activities in FY2024 was mainly due to purchase of property, plant and equipment related to the construction of the new 100,000 tons Methylamine plant.

Net cash generated from financing activities in FY2024 was mainly due to drawdown of bank borrowings, bill payables to banks and decrease in pledge fixed deposits partially offset with repayment of bank borrowings and repayment of bill payables to banks.

5. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

There was no forecast or prospect statement previously disclosed to shareholders.

6. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next operating period and the next 12 months

The Group's financial performance remains under pressure due to low prices across its major product lines. This is largely attributed to a broad economic slowdown in China that has weakened industry-wide demand, compounded by an increased supply from new competitors. In response, the Group has taken proactive steps, such as reducing and/or halt production and cutting operational costs to mitigate losses and better align its output with current market demand, thereby safeguarding financial stability in a challenging environment.

On a brighter note, with the Chinese government introducing policies to stimulate economic growth, there is an expectation that the current downturn in product prices will gradually ease. However, broader macroeconomic challenges including trade tensions, geopolitical conflicts, and other uncertainties continue to pose external risks.

In view of the above, the business environment for the current financial year remains challenging. Going forward, the Group will continue to monitor market conditions closely and adapt its business strategies as and when appropriate.

F. Other Information Required by Listing Rule Appendix 7C

7.Dividend information

7a. Whether an interim (final) ordinary dividend has been declared (recommended; and No final dividends have been declared or recommended for the financial year ended 31 December 2024.

7b. (i) Amount per share (cents)
Not applicable

7b. (ii) previous corresponding period (cents)
Not applicable

7c. Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).
Not applicable

7d The date the dividend is payable.
Not applicable

7e The date on which Registrable Transfers received by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.
Not applicable

8. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.

The Board does not recommend any final dividend for FY2024 as the Group wishes to reserve adequate resources for the Group's ongoing projects and respond to any adverse changes in the macroeconomic environment.

F. Other Information Required by Listing Rule Appendix 7C
9. Interested person transactions

The Company had at its annual general meeting held on 25 April 2024 obtained shareholders' approval for the renewal of the general mandate for IPTs. Save as disclosed below, there are no other IPTs equal to or above S\$100,000 in FY2023.

| Name of interested person / Nature of relationship | Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920) | Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000) |
|--|--|--|
| | FY2024 | FY2024 |
| Anyang Chemical Industry Group Co., Ltd ("Anhua") ⁽¹⁾ | Security and fire protection service fees RMB 4.93 million | Sales of Repair Material, industrial steams and electricity RMB 5.37 million |
| | Project consultation fees RMB 3.68 million | Purchase of Raw Materials I and II RMB 3.49 million |
| | | Purchase of Repair Materials RMB 9.18 million |
| | | Rental income of equipment RMB 0.75 million |
| | | Rental expense of equipment RMB 18.93 million |
| Anyang Jiulong Chemical Co., Ltd ("Anyang Jiulong") ⁽²⁾ | Nil | Sale of Dimethylamine, Repair Materials and electricity RMB 10.85 million |
| | | Purchase of Raw Materials I and II RMB 19.38 million |
| | | Rental of equipment RMB 0.96 million |
| Total | RMB 8.61 million | |

Notes:

- (1) Anhua is the holding company of Anyang Longyu (HK) Development Co., Ltd. ("**Anyang Longyu**"), a controlling shareholder of the Company. Anyang Longyu holds approximately 25.27% of the issued share capital of the Company.
- (2) Anyang Jiulong is a joint venture between Jiutian Chemical Group Limited and Anhua and Henan Energy and Chemical Industry Group Co., Ltd. ("**HNEC**") pursuant to which Anhua holds 15.9% and HNEC holds 35.1% and Jiutian Chemical Group Limited holds 49% of the registered capital of Anyang Jiulong. HNEC is the parent of Anhua.

F. Other Information Required by Listing Rule Appendix 7C

10. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that it has procured undertakings from all its directors and executive officers in the required format.

11. Disclosures on Acquisition and Realisation of Shares pursuant to Catalyst Rule 706A

Except for the Company's announcement on 14 November 2024 regarding the members' voluntary winding up of an associated company, Anyang Jiujiu Chemical Technology Co., Ltd., the Company did not acquire any shares that resulted in any entity becoming a subsidiary or associated company, nor did it increase its shareholding percentage in any subsidiary during FY2024. Additionally, please refer to the Company's announcement dated on 14 November 2024.

12. A breakdown of sales

The following table shows the breakdown of sales and net profit during the first and second halves of FY2024 and FY2023.

| Group | FY2024 RMB'000 | FY2023 RMB'000 | % (decrease) |
|--|-------------------|-------------------|-----------------|
| a) Sales reported for first half year | 62,167 | 393,127 | (84) |
| b) Operating loss after tax before deducting non-controlling interests reported for first half year | 84,536 | 162,374 | (48) |
| c) Sales reported for second half year | 181,590 | 205,436 | (12) |
| d) Operating loss after tax before deducting non-controlling interests reported for second half year | 63,264 | 184,355 | (66) |

13. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704 (10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

The Board of Directors confirms that there is no person occupying managerial position in the Company or any of its principal subsidiaries who is a relative of a director, executive officer or substantial shareholder of the Company during the financial year and up to the date of this announcement.

F. Other Information Required by Listing Rule Appendix 7C

14. Use of Net Proceeds

The following relates to the net proceeds of S\$9.97 million raised from the Placement that was completed on 27 October 2020:

| Purpose | Amount allocated (S\$'000) | Net proceeds utilised as at the date of announcement (S\$'000) | Balance unutilised (S\$'000) |
|--------------------------------|---------------------------------------|---|---|
| <u>Working Capital</u> | | | |
| - Wages and staff related cost | | 3,214 | |
| - Directors' fee | | 901 | |
| - Office rental | | 363 | |
| - Professional fees | | 1,307 | |
| - Other office expenses | | 690 | |
| Total | 9,967 | 6,475 | 3,492 |

The use of proceeds is consistent with the Company's proposed use of funds as set out in the announcement dated 27 October 2020.

BY ORDER OF THE BOARD

XU AIJUN
Non-executive and
Non-independent Chairman
20 February 2025

This announcement has been reviewed by the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.